3-氯吡啶-4-硼酸频哪酯 | 458532-90-6

• 物质功能分类: 医药中间体 - 杂环化合物 - 吡啶类化合物
• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 中文名称: 3-氯吡啶-4-硼酸频哪酯
• 中文别名: 3-氯-4-吡啶硼酸频哪醇酯；3-氯吡啶-4-硼酸频哪酯,95%
• 英文名称: 3-chloro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridine
• CAS: 458532-90-6
• 化学式: C₁₁H₁₅BClNO₂
• mdl: MFCD06798249
• 分子量: 239.51
• InChiKey: VUWRRLUCWJCPMF-UHFFFAOYSA-N

物化性质

• 熔点：
  103-108°C
• 沸点：
  324.4±27.0 °C(Predicted)
• 密度：
  1.14±0.1 g/cm3(Predicted)
• 稳定性/保质期：
  按规定使用和贮存不会分解，避免接触氧化物。

计算性质

• 辛醇/水分配系数(LogP)：
  3.11
• 重原子数：
  16
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.545
• 拓扑面积：
  31.4
• 氢给体数：
  0
• 氢受体数：
  3

安全信息

• 危险品标志：
  Xi
• 安全说明：
  S26
• 危险类别码：
  R36/37/38
• WGK Germany：
  2
• 海关编码：
  2934999090
• 危险性防范说明：
  P261,P305+P351+P338
• 危险性描述：
  H315,H319,H335
• 储存条件：
  存放在密闭、阴凉、干燥的地方。

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
Product Name: 3-Chloropyridine-4-boronic acid, pinacol ester
Synonyms:

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.
H315: Causes skin irritation
H319: Causes serious eye irritation
H335: May cause respiratory irritation
P261: Avoid breathing dust/fume/gas/mist/vapours/spray
P305+P351+P338: IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses if present
and easy to do – continue rinsing

---

Section 3. Composition/information on ingredients.
Ingredient name: 3-Chloropyridine-4-boronic acid, pinacol ester
CAS number: 458532-90-6

---

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
Eye contact:
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels, under −20◦C.
Storage:

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Appearance: Not specified
No data
Boiling point:
Melting point: No data
Flash point: No data
Density: No data
Molecular formula: C11H15BClNO2
Molecular weight: 239.5

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides, hydrogen chloride.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  3-氯吡啶-4-硼酸频哪酯 在 三甲基氯硅烷 、 1,1'-双(二苯膦基)二茂铁二氯化钯(II)二氯甲烷复合物 、 potassium carbonate 、 sodium iodide 作用下， 以 1,4-二氧六环 、 水 、 乙腈 为溶剂， 反应 2.0h， 生成 ethyl 4-(3-chloropyrid-4-yl)-6-oxo-5,6-dihydro-1,5-naphthyridine-3-carboxylate
  参考文献：
  名称：

  由Pd催化的Suzuki-Miyaura偶联和Cu催化的酰胺化反应从4-溴-6-甲氧基-1,5-萘啶-3-羧酸乙酯中分三步合成乙基3-羟基蒽酮

  摘要：

  通过三步法，由易于制备的4-溴-6-甲氧基-1,5-萘啶-3-羧酸乙酯（2b）制备了canthin-6--1--1-羧酸乙酯（1b）和9个类似物1c - k。非经典方法集中于使用Pd催化的Suzuki-Miyaura偶联和Cu催化的C-N偶联来构建中心吡咯（B环）。此外，用NaOH在DCM / MeOH（9：1）中处理芸苔酮-1-羧酸乙酯1b以高收率得到了芸苔酮-6--1--1-羧酸（6）。所有化合物均已充分表征。

  DOI：

  10.1021/jo200824b
• 作为产物：
  描述：

  3-氯吡啶 在 lithium diisopropyl amide 作用下， 以 四氢呋喃 、 正己烷 为溶剂， 反应 2.0h， 生成 3-氯吡啶-4-硼酸频哪酯
  参考文献：
  名称：

  定向邻位金属化，硼化和吡啶类化合物的铃木-宫浦交叉耦合：一锅议定书替补Azabiaryls ＃

  摘要：

  描述了通过一锅法合成氮杂双芳基化合物19a - t的一般方法，该方法涉及定向原金属化（D o M）-硼化-铃木-宫浦交叉偶联序列。除了三种异构的吡啶基羧酰胺15a - c外，氯-，氟-和O-氨基甲酰基吡啶也适用于该方法，提供了一系列的氮杂双芳基（表2）。该方法的优点在于，避免了公认的吡啶基硼酸的分离困难及其对脱硼的不稳定性。hydroxypicolinamides的有效合成12 - 14（方案3）通过LDA-B（O i）的一锅金属化-硼化-氧化顺序PR）3原位避免初期的自缩合过程邻-metalated物种（方案2）是描绘。证明了通过定向远程金属化方案将氮杂双芳基19b，e，h，l转化为氮杂芴酮20b，e，h，l（表3）。给出了对当代杂环合成化学相当感兴趣的硼酸吡啶基酯的综合研究结果（图1）。

  DOI：

  10.1021/jo0620359

文献信息

• [EN] NEW COMPOUNDS FOR TREATMENT OF DISEASES RELATED TO DUX4 EXPRESSION<br/>[FR] NOUVEAUX COMPOSÉS POUR LE TRAITEMENT DE MALADIES LIÉES À L'EXPRESSION DE DUX4
  申请人：FACIO INTELLECTUAL PROPERTY B V

  公开号：WO2021105474A1

  公开（公告）日：2021-06-03

  The present invention relates to compounds for the treatment of diseases related to DUX4 expression, such as muscular dystrophies. It also relates to use of such compounds, or to methods of use of such compounds.

  本发明涉及用于治疗与DUX4表达相关疾病的化合物，如肌肉萎缩症。它还涉及使用这些化合物，或者使用这些化合物的方法。
• [EN] SUBSTITUTED 4,5,6,7-TETRAHYDRO-PYRAZOLO[1,5-a]PYRAZINE DERIVATIVES AND 5,6,7,8-TETRAHYDRO-4H-PYRAZOLO[1,5-a][1,4]DIAZEPINE DERIVATIVES AS ROS1 INHIBITORS<br/>[FR] DÉRIVÉS 4,5,6,7-TÉTRAHYDRO-PYRAZOLO[1,5-A]PYRAZINE SUBSTITUÉS ET DÉRIVÉS 5,6,7,8-TÉTRAHYDRO-4H-PYRAZOLO[1,5-A][1,4]DIAZÉPINE UTILISÉS COMME INHIBITEURS DE ROS1
  申请人：JANSSEN PHARMACEUTICA NV

  公开号：WO2015144799A1

  公开（公告）日：2015-10-01

  The present invention relates to substituted 4,5,6,7-tetrahydro-pyrazolo[1,5-a]pyrazine derivatives and 5,6,7,8-tetrahydro-4H-pyrazolo[1,5-a][1,4]diazepine derivatives of formula (I) wherein the variables have the meaning defined in the claims. The compounds according to the present invention are useful as ROS 1 inhibitors. The invention further relates to processes for preparing such novel compounds, pharmaceutical compositions comprising said compounds as an active ingredient as well as the use of said compounds as a medicament.

  本发明涉及取代的4,5,6,7-四氢吡唑并[1,5-a]吡嗪衍生物和5,6,7,8-四氢-4H-吡唑并[1,5-a][1,4]二氮杂环衍生物的公式(I)中的变量具有权利要求中定义的含义。根据本发明的化合物可用作ROS 1抑制剂。本发明还涉及制备这种新化合物的方法，包含所述化合物作为活性成分的药物组合物，以及将所述化合物用作药物的用途。
• Discovery of N-(5,6-diarylpyridin-2-yl)amide derivatives as potent and selective A2B adenosine receptor antagonists
  作者：Paul Eastwood、Jacob Gonzalez、Sergio Paredes、Arsenio Nueda、Teresa Domenech、Joan Alberti、Bernat Vidal

  DOI：10.1016/j.bmcl.2010.01.045

  日期：2010.3

  The synthesis and SAR of a series of N-(5,6-diarylpyridin-2-yl)amide derivatives as potent A2B adenosine receptor antagonists is described. Several compounds showed good selectivity versus other adenosine receptors. The potent and selective analogue 9 was shown to have good oral bioavailability in the rat.

  描述了作为有效的A 2B腺苷受体拮抗剂的一系列N-（5,6-二芳基吡啶-2-基）酰胺衍生物的合成和SAR 。与其他腺苷受体相比，几种化合物具有良好的选择性。强有力的和选择性的类似物9被证明在大鼠中具有良好的口服生物利用度。
• [EN] REV-ERB AGONISTS FOR THE TREATMENT OF TH17-MEDIATED INFLAMMATORY DISORDERS<br/>[FR] AGONISTES REV-ERB POUR LE TRAITEMENT DE TROUBLES INFLAMMATOIRES À MÉDIATION PAR TH17
  申请人：SCRIPPS RESEARCH INST

  公开号：WO2021263278A1

  公开（公告）日：2021-12-30

  The present disclosure provides compounds of Formula IA and Formula IB and their pharmaceutical compositions as selective agonists of REV-ERB-α: where R1, R2, R3, R4, R5, RX1, RX2, nA, nB, X, Y, and Z are described herein. The compounds are useful in various methods and uses, such as in the treatment of diseases including hyperglycemia, dyslipidemia, atherosclerosis, and autoimmune and inflammatory disorders or diseases, and as cancer therapeutics, such as for the treatment of glioblastoma, hepatocellular carcinoma, and colorectal cancer, and for immune-oncology purposes.

  本公开提供了Formula IA和Formula IB的化合物及其作为REV-ERB-α选择性激动剂的药物组合物：其中R1、R2、R3、R4、R5、RX1、RX2、nA、nB、X、Y和Z如本文所述。这些化合物在各种方法和用途中非常有用，例如用于治疗包括高血糖、血脂异常、动脉粥样硬化、自身免疫和炎症性疾病等疾病，以及作为癌症治疗药物，如用于治疗胶质母细胞瘤、肝细胞癌和结直肠癌，以及用于免疫肿瘤学目的。
• [EN] CaMKII INHIBITORS AND USES THEREOF<br/>[FR] INHIBITEURS CAMKII ET LEURS UTILISATIONS
  申请人：ALLOSTEROS THERAPEUTICS INC

  公开号：WO2016037106A1

  公开（公告）日：2016-03-10

  The present invention provides compounds useful as inhibitors of Ca2+/calmodulin-dependent protein kinase (CaMKII), compositions thereof, and methods of using the same.

  本发明提供了作为Ca2+/钙调蛋白激酶（CaMKII）抑制剂的化合物，以及这些化合物的组合物和使用方法。